CGMs: Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group

Sponsor
Hamad Medical Corporation (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT03141398
Collaborator
(none)
0
16

Study Details

Study Description

Brief Summary

A prospective, observational, comparative study with no intervention.The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C (Glycated Hemoglobin) and their relation to iron overload detected by T2* MRI of the pancreas in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies, Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status. Using Validated Tools with Permission, the participants will be selected through probability (random) sampling method with expected subjects numbers ALL/L: 30-50, Thalassemia Major: 20, Sickle cell disease: 20.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Continuous Glucose Monitoring (CGM)
  • Diagnostic Test: Oral Glucose Tolerance Test (OGTT)
  • Diagnostic Test: T2* MRI of the Pancreas

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Continuous Glucose Monitoring (CGM) Versus Oral Glucose Tolerance Test (OGTT) Versus T2* MRI Of The Pancreas In High-Risk Group (Hemoglobinopathies, Lymphoma & Acute Lymphoblastic Leukemia): A Comparative Study
Anticipated Study Start Date :
Aug 1, 2017
Anticipated Primary Completion Date :
Aug 1, 2018
Anticipated Study Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
High-Risk Group

The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.

Diagnostic Test: Continuous Glucose Monitoring (CGM)
Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.

Diagnostic Test: Oral Glucose Tolerance Test (OGTT)
Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.

Diagnostic Test: T2* MRI of the Pancreas
MRI [Magnetic resonance imaging] of the pancreas which is safe and takes around 30 minutes.

Outcome Measures

Primary Outcome Measures

  1. Efficiency of continuous glucose monitoring compared to oral glucose tolerance and MRI of the Pancreas [12 Months]

    Compare the efficiency of detecting glycemic abnormalities using CGMS versus OGTT vs HbA1C. in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance. Detect the prevalence of glycemic abnormalities detected in the same group of patients (high-risk patients) using three different modalities of testing (CGMS, OGTT, HbA1C)and T2*MRI for pancreas

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • This study will include participants who are High-risk patients to develop glycemic abnormalities:
  1. Thalassemia major and SCD (beta cell toxicity and hepatic siderosis)

  2. ALL/L ( beta cell injury and hepatic injury due to chemotherapy, and insulin resistance due to corticosteroids)

Exclusion Criteria:
  • Age < 14 years;

  • Other systemic diseases, renal disorders or malnourished;

  • Patients and unwilling to participate in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Hamad Medical Corporation

Investigators

  • Principal Investigator: Mohamed Yassin, Hamad Medical Corporation

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hamad Medical Corporation
ClinicalTrials.gov Identifier:
NCT03141398
Other Study ID Numbers:
  • 16298/16
First Posted:
May 5, 2017
Last Update Posted:
Jul 26, 2017
Last Verified:
May 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 26, 2017